CatSper-Based Contraceptive Vaccine
- User: Female/Male
- Hormonal: Non-Hormonal
-
Delivery type:
- Injectable
-
Intended Duration:
- Long-Acting
- Development Stage: Discovery & Early Development
- Developer(s)/researcher(s): Rensselaer Polytechnic Institute, Yale University
Details
- API: CatSper Antigen
- Target: CatSper Channel
-
Mechanism of Action:
- Anti-Microbial
- Inhibition of Sperm Capacitation
- Inactive Materials: Not Yet Determined
- Regimen: Not Yet Determined
- MPT: Not Potential MPT
- Promising Attributes: Developers believe an anti-sperm vaccine could provide long-term contraceptive effect in both male and female users with fewer side effects.
Product Status
Developer Confirms to CTI Exchange that Development is Inactive
History
The Bystroff Lab at Rensselaer Polytechnic Institute has led CatSper-focused contraceptive vaccine development since at least 2018. In partnership with Yale, recombinant vaccine candidates have been tested in Balb/C mice, with one candidate showing contraceptive efficacy. Results from this evaluation, published in 2023, suggested potential viability of an anti-CatSper vaccine for long-term contraceptive protection. Development is inactive as of 2026, confirmed by developer.